哪些老年人面临处方级联风险最高?一项关于加巴喷丁类-袢利尿剂级联的全国性研究
本研究基于2010-2019年美国退伍军人事务部和医疗保险理赔数据,纳入≥66岁启动加巴喷丁类药物的退伍军人,采用处方序列对称分析评估加巴喷丁类-袢利尿剂级联。结果显示调整序列比为1.23(95%CI 1.13-1.34),提示级联存在;≥85岁者发生级联可能性较低(aOR 0.74,95%CI 0.56-0.96),而服用≥10种药物者可能性较高(aOR 1.39,95%CI 1.07-1.82)。
要点
- 加巴喷丁类启动后6个月内启动袢利尿剂的患者数多于启动前6个月内启动者,支持处方级联存在。
- ≥85岁老年人发生该级联的风险低于66-74岁者(aOR 0.74,95%CI 0.56-0.96)。
- 服用≥10种药物者发生该级联的风险高于服用0-4种药物者(aOR 1.39,95%CI 1.07-1.82)。
核心结论
- 在老年退伍军人中,较年轻和服用多种药物者可能面临更高的加巴喷丁类-袢利尿剂级联风险,该级联可加重多重用药和潜在药物相关伤害。
- 未发现该级联的强预测因素,提示处方级联预防措施应广泛实施而非聚焦特定亚组。
研究设计与样本
- 使用退伍军人事务部和医疗保险理赔数据(2010-2019年)的处方序列对称分析(PSSA),纳入≥66岁启动加巴喷丁类的退伍军人。
- 采用多变量逻辑回归,以处方顺序为二分类因变量,计算调整比值比(aOR)探索高风险组。
主要发现
- 151,442名启动加巴喷丁类的退伍军人中,启动后6个月内启动袢利尿剂者1,981例,启动前6个月内启动者1,599例。
- 加巴喷丁类-袢利尿剂组平均年龄73岁,98%为男性,13%为黑人,5%为西班牙裔,80%为白人。
- 两组患者特征和卫生服务利用因素相似(所有比较标准化均数差<0.10)。
- 调整序列比(aSR)为1.23(95%CI 1.13-1.34),强烈提示级联存在。
关键数值与推荐
- 与66-74岁相比,≥85岁者发生级联的可能性较低(aOR 0.74,95%CI 0.56-0.96)。
- 与服用0-4种药物相比,服用≥10种药物者发生级联的可能性较高(aOR 1.39,95%CI 1.07-1.82)。
临床怎么用
- 对启动加巴喷丁类的老年患者,尤其是较年轻和多重用药者,应警惕随后启动袢利尿剂可能反映处方级联而非新发适应症。
- 处方级联预防策略宜在老年患者中广泛推行,而非仅针对特定亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prescribing cascades are important contributors to polypharmacy. Little is known about which older adults are at highest risk of experiencing prescribing cascades. We explored which older veterans are at highest risk of the gabapentinoid (including gabapentin and pregabalin)-loop diuretic (LD) cascade, given the dramatic increase in gabapentinoid prescribing in recent years. METHODS: Using Veterans Affairs and Medicare claims data (2010-2019), we performed a prescription sequence symmetry analysis (PSSA) to assess loop diuretic initiation before and after gabapentinoid initiation among older veterans (≥66 years). To identify the cascade, we calculated the adjusted sequence ratio (aSR), which assesses the temporality of LD relative to gabapentinoid initiation. To explore high-risk groups, we used multivariable logistic regression with prescribing order modeled as a binary dependent variable. We calculated adjusted odds ratios (aORs), measuring the extent to which factors are associated with one prescribing order versus another. RESULTS: Of 151,442 veterans who initiated a gabapentinoid, there were 1,981 patients who initiated a LD within 6 months after initiating a gabapentinoid compared to 1,599 patients who initiated a LD within 6 months before initiating a gabapentinoid. In the gabapentinoid-LD group, the mean age was 73 years, 98% were male, 13% were Black, 5% were Hispanic, and 80% were White. Patients in each group were similar across patient and health utilization factors (standardized mean difference <0.10 for all comparisons). The aSR was 1.23 (95% CI: 1.13, 1.34), strongly suggesting the cascade's presence. People age ≥85 years were less likely to have the cascade (compared to 66-74 years; aOR 0.74, 95% CI: 0.56-0.96), and people taking ≥10 medications were more likely to have the cascade (compared to 0-4 drugs; aOR 1.39, 95% CI: 1.07-1.82). CONCLUSIONS: Among older adults, those who are younger and taking many medications may be at higher risk of the gabapentinoid-LD cascade, contributing to worsening polypharmacy and potential drug-related harms. We did not identify strong predictors of this cascade, suggesting that prescribing cascade prevention efforts should be widespread rather than focused on specific subgroups.
引用
- Growdon ME, Jing B, Morris EJ, et al. Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid-loop diuretic cascade. J Am Geriatr Soc. 2024. PMID: 38547357. doi:10.1111/jgs.18892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。